TY  - JOUR
N1  - Copyright © 2017. This manuscript version is published under a Creative Commons Attribution Non-commercial Non-derivative 4.0 International licence (CC BY-NC-ND 4.0). This licence allows you to share, copy, distribute and transmit the work for personal and non-commercial use providing author and publisher attribution is clearly stated. Further details about CC BY licences are available at http://creativecommons.org/licenses/by/4.0. Access may be initially restricted by the publisher.
EP  - 135
VL  - 55
AV  - public
SP  - 128
Y1  - 2017/03/16/
TI  - Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential
KW  - Combinatory treatment
KW  -  Drug delivery system
KW  -  RNA
KW  -  Synergy
KW  -  Therapeutic substance
KW  -  Tumor
A1  - Larsson, M
A1  - Huang, W-T
A1  - Liu, D-M
A1  - Losic, D
JF  - Cancer Treatment Reviews
SN  - 1532-1967
UR  - http://doi.org/10.1016/j.ctrv.2017.03.004
ID  - discovery1549825
N2  - Gene-silencing miRNA and siRNA are emerging as attractive therapeutics with potential to suppress any genes, which could be especially useful in combination cancer therapy to overcome multidrug resistant (MDR) cancer. Nanomedicine aims to advance cancer treatment through functional nanocarriers that delivers one or more therapeutics to cancer tissue and cells with minimal off-target effects and suitable release kinetics and dosages. Although much effort has gone into developing circulating nanocarriers with targeting functionality for systemic administration, another alternative and straightforward approach is to utilize formulations to be administered directly to the site of action, such as pulmonary and intratumoral delivery. The combination of gene-silencing RNA with drugs in nanocarriers for localized delivery is emerging with promising results. In this review, the current progress and strategies for local co-administration of RNA and drug for synergistic effects and future potential in cancer treatment are presented and discussed. Key advances in RNA-drug anticancer synergy and localized delivery systems were combined with a review of the available literature on local co-administration of RNA and drug for cancer treatment. It is concluded that advanced delivery systems for local administration of gene-silencing RNA and drug hold potential in treatment of cancer, depending on indication. In particular, there are promising developments using pulmonary delivery and intratumoral delivery in murine models, but further research should be conducted on other local administration strategies, designs that achieve effective intracellular delivery and maximize synergy and feasibility for clinical use.
ER  -